tirzepatide and crohn's disease Disease: Safety Guide Frontiers | GLP-1 receptor agonists
Description
Clinical evidence supports its use across a broad population, making it accessible to many people seeking weight loss support
doi: 10.1210/endo.139.9.6288
Discontinuation rate: 18% Wegovy , 25.5% placebo
The glucagon receptor is why and retatrutide is the only obesity drug that activates it
The health secretary, Wes Streeting, said: Our widening waistbands are also placing significant burden on our health service, costing the NHS 11bn a year even more than smoking
Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA
